BREAKING: Kimberly‑Clark Corporation has agreed to acquire Kenvue Inc. — the parent company of Tylenol — in a staggering $48.7 billion cash-and-stock deal.
What makes this move even more striking: it comes just weeks after renewed public controversy surrounding Tylenol and alleged autism-risks.
So what’s really going on? Is Kimberly-Clark buying a brand — or quietly burying a problem?
With Kenvue’s portfolio of household names (Tylenol, Neutrogena, Listerine…) now merging with Kimberly-Clark’s Kleenex / Huggies empire, the combined operation is projected to generate more than $32 billion in revenue.
But investors aren’t all convinced: risks remain from litigation, integration and regulatory fallout.
Stay tuned — this deal might reshape consumer-health forever
